| Symbol | ANRO |
|---|---|
| Name | ALTO NEUROSCIENCE, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW, California, 94041, United States |
| Telephone | +1 650 200-0412 |
| Fax | — |
| — | |
| Website | https://www.altoneuroscience.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001999480 |
| Description | Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients brain activity and behavior to better identify which patients are more likely to respond to our novel product candidates. Additional info from NASDAQ: |
Alto Neuroscience, Inc. - Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Read moreAlto Neuroscience Announces Participation in Upcoming Investor Conferences
Read moreAlto Neuroscience, Inc. - Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
Read moreAlto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
Read moreNew Form SCHEDULE 13G/A - Alto Neuroscience, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-352632 <b>Size:</b> 11 KB
Read moreNew Form SCHEDULE 13G/A - Alto Neuroscience, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000902664-26-003498 <b>Size:</b> 10 KB
Read moreNew Form SCHEDULE 13G/A - Alto Neuroscience, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000919574-26-005199 <b>Size:</b> 11 KB
Read more(30% Negative) ALTO NEUROSCIENCE, INC. (ANRO) Reports Q3 2026 Financial Results
Read moreAlto Neuroscience, Inc. - Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Read moreAlto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Read more| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Apollo Armband | DEVICE | Approved | Fatigue | COMPLETED | NCT04983342 |
| Apollo Wearable | DEVICE | Approved | Stress Disorders, Post-Traumatic | RECRUITING | NCT05274230 |